Cargando…
Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
BACKGROUND: Treatment of chronic severe pediatric ITP is not well studied. In a phase 1/2 12–16-week study, 15/17 romiplostim-treated patients achieved platelet counts ≥50 × 10(9)/L, and romiplostim treatment was well tolerated. In a subsequent open-label extension (≤109 weeks), 20/22 patients recei...
Autores principales: | Bussel, James B, Hsieh, Loan, Buchanan, George R, Stine, Kimo, Kalpatthi, Ram, Gnarra, David J, Ho, Richard H, Nie, Kun, Eisen, Melissa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309514/ https://www.ncbi.nlm.nih.gov/pubmed/25345874 http://dx.doi.org/10.1002/pbc.25136 |
Ejemplares similares
-
Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017) -
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies
por: Kuter, David J., et al.
Publicado: (2019) -
The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation
por: Yamaguchi, Masaru, et al.
Publicado: (2018) -
Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry
por: Doobaree, Indraraj Umesh, et al.
Publicado: (2019) -
Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects
por: Jawa, Vibha, et al.
Publicado: (2010)